Duval_CIBMTR_Score_for_Acute_Myelogenous_Leukemia_AML_Survival v.1

Predicts overall survival in AML patients with relapsed/refractory disease undergoing myeloablative transplant.

Henrik Honkanen

henrik.honkanen@stud.ki.se

@Cambio CDS

To predict the overall survival in AML patients with relapsed/refractory disease undergoing myeloablative transplant.

Use in patients with relapsed or refractory active AML for whom hematopoietic stem cell transplant (HSCT) is being considered. Score interpretation: -Duval Score 0 - 3-year overall survival after transplantation 42% -Duval Score 1 - 3-year overall survival after transplantation 28% -Duval Score 2 - 3-year overall survival after transplantation15% -Duval Score ≥3 - 3-year overall survival after transplantation 6%

Do not use in patients with chronic myelogenous leukemia (CML) in blast crisis.

1. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, De Lima M, Gupta V, Keating A. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. Journal of clinical oncology. 2010 Aug 10;28(23):3730.

OBSERVATION.duval_cibmtr_score_for_acute_myelogenous_leukemia_aml_survival.v0